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A B S T R A C T
Chronic stress is often accompanied by gastrointestinal symptoms, which might be due to stress-induced shift of
gut microbiome to pathogenic bacteria. It has been hypothesized that stress alters gut permeability and results in
mild endotoxemia which exaggerates HPA activity and contributes to anxiety and depression. To reveal the
relationship between microbiome composition, stress-induced gastrointestinal functions and behavior, we
treated chronically stressed mice with non-absorbable antibiotic, rifaximin. The “two hits” stress paradigm was
used, where newborn mice were separated from their mothers for 3 h daily as early life adversity (maternal
separation, MS) and exposed to 4 weeks chronic variable stress (CVS) as adults. 16S rRNA based analysis of gut
microbiome revealed increases of Bacteroidetes and Proteobacteria and more speciﬁcally, Clostridium species in
chronically stressed animals. In mice exposed to MS + CVS, we found extenuation of colonic mucosa, increased
bacterial translocation to mesenteric lymph node, elevation of plasma LPS levels and inﬁltration of F4/80 po-
sitive macrophages into the colon lamina propria. Chronically stressed mice displayed behavioral signs of an-
xiety-like behavior and neophobia. Rifaximin treatment decreased Clostridium concentration, gut permeability
and LPS plasma concentration and increased colonic expression of tight junction proteins (TJP1, TJP2) and
occludin. However, these beneﬁcial eﬀects of rifaximin in chronically stressed mice was not accompanied by
positive changes in behavior. Our results suggest that non-absorbable antibiotic treatment alleviates stress-in-
duced local pathologies, however, does not aﬀect stress-induced behavior.
1. Introduction
There is a functionally relevant communication between gastro-
intestinal tract (GIT), gut microbiome and central nervous system, re-
ferred to as gut-brain axis (Bravo et al., 2012; Cryan and O'Mahony,
2011). This communication occurs via enteric-, autonomic-, neu-
roendocrine- and immune system pathways (Rieder et al., 2017). An
increasing number of studies indicate that chronic stress aﬀects com-
position and microbial balance of gut microbiome and may lead to
serious dysbiosis (Bharwani et al., 2016; Golubeva et al., 2015; Mayer
et al., 2014). In addition, chronic psychological stress and early life
adversity result in speciﬁc behavioral alterations, by increasing anxiety
and depressive symptoms (McCormick and Green, 2013; Slattery et al.,
2012; Strekalova et al., 2004), changes in coping strategy (Cerniauskas
et al., 2019; Winkler et al., 2017) and cognition (Herman et al., 1995;
Sandi, 2004). Although these stress-induced psychopathologies in
human are accompanied by changes in the microbiome, the cause and
eﬀect relationship still remains unknown (Rieder et al., 2017). In
https://doi.org/10.1016/j.bbi.2019.12.004
Received 27 August 2019; Received in revised form 29 November 2019; Accepted 4 December 2019
Abbreviations: AMP, Antimicrobial peptide; BAT, Brown adipose tissue; CVS, Chronic variable stress; EDTA, Ethylenediaminetetraacetic acid; eWAT, Epididymal
white adipose tissue; GAPDH, Glyceraldehyde 3-phosphate dehydrogenase; GIT, Gastrointestinal tract; H&E, Hematoxylin & eosin; IBS, Irritable bowel syndrome;
LAL, Limulus amebocyte lysate (assay); LPS, Lipopolysaccharide; MD, Minimal disease; MLN, Mesenteric lymph node; MS, Maternal separation; NCBI, National
Center for Biotechnology Information; OF, Open ﬁeld test; PND, Post natal day; RIA, Radioimmunoassay; RPLP1, Ribosomal protein, large, P1; sWAT, Subcutaneous
white adipose tissue; TG, Triglyceride; TJP1-3, Tight junction protein 1-3; TLR4, Toll-like receptor 4
⁎ Corresponding author.
E-mail address: kovacs@koki.hu (K.J. Kovács).
Brain, Behavior, and Immunity xxx (xxxx) xxx–xxx
0889-1591/ © 2019 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license 
(http://creativecommons.org/licenses/BY-NC-ND/4.0/).
Please cite this article as: Dániel Kuti, et al., Brain, Behavior, and Immunity, https://doi.org/10.1016/j.bbi.2019.12.004
laboratory rodents, some of stress-induced behavioral alterations can be
“transmitted” to normal animals by fecal transplants, indicating a role
of the microbiome in shaping behavioral performance (Langgartner
et al., 2018).
Along with changes in the microbiome, chronic stress inﬂuence host
barrier functions and result in “leaky gut” which underpins the chro-
nic low-grade inﬂammation, observed in stress-related anxiety and de-
pression (Kelly et al., 2015; Leclercq et al., 2012). Proinﬂammatory
mediators, released in response to endotoxemia, increase hypothalamo-
pituitary-adrenocortical axis activity and may exaggerate hormonal and
behavioral stress responses. Though the ﬁeld advanced in the past ten
years, the speciﬁc, complex relationship between stress, gut micro-
biome, inﬂammation and brain function is still not fully revealed
(Moloney et al., 2016; Scott et al., 2017; Slyepchenko et al., 2016). For
instance, it is not known if overgrowth of pathogenic bacteria at the
expense of commensals interferes with neuroendocrine, immune and
behavioral changes during chronic stress.
Rifaximin is a non-absorbable, non-systemic, GIT-speciﬁc antibiotic,
which selectively eliminates pathogenic bacteria (Kane and Ford, 2016)
and relieves diarrhea associated with Clostridium diﬃcile infections
(Rubin et al., 2011). More recently, microbiome-independent anti-in-
ﬂammatory eﬀects of rifaximin have also been reported in cases of post-
infection diarrhea (Jin et al., 2018).
Emerging studies indicate that psychobiological functions can be
manipulated through the microbiome (Dinan et al., 2013; Warda et al.,
2019), therefore, the aim of this study was to test the hypothesis if
rifaximin treatment restores chronic stress-induced gastrointestinal and
inﬂammatory symptoms and changes in microbiome along with stress-
induced changes in anxiety-like behavior.
2. Materials and methods
2.1. Experimental animals
Experiments were performed on male C57BL/6J mice. Animals were
born and housed at the minimal disease (MD) level of Medical Gene
Technology Unit at the Institute of Experimental Medicine. All experi-
mental animals were from second litter of the breeding pairs. On PND0
the litter size was equalized to 5 by removing female oﬀspring. After
weaning at 21 days postnatal, male mice were housed 2–3/cage in 12 h
light/dark cycle (lights on from 6 a.m. to 6p.m.) at 21–22 °C with hu-
midity. Animals received standard pelleted rodent chow (VRF1, Special
Diets Services (SDS), Witham, Essex, UK) containing 19,1 g% protein,
55,3 g% carbohydrate and 4,8 g% fat. Chow and water were provided
ad libitum. Experiments were complied with the ARRIVE guidelines and
performed in accordance with the guidelines of European Communities
Council Directive (86/609 EEC), EU Directive (2010/63/EU) and the
Hungarian Act of Animal Care and Experimentation (1998; XXVIII,
Sect. 243/1998). All procedures and experiments were approved by the
Animal Care and Use Committee of the Institute of Experimental
Medicine, Hungarian Academy of Sciences (permit number: PEI/001/
29-4/2013).
2.2. Experimental design
In this experiment “two hits chronic stress paradigm” was used.
Starting at postnatal day 1, pups were separated from their mother
(maternal separation MS) for 3 h daily for 12 days (early life stress - ﬁrst
hit). Pups were weaned at 21 days and kept 2–3/cage. At the age of
50 days, mice were exposed to chronic variable stress paradigm (CVS –
second hit). In CVS, mice were stressed for 4 weeks, two times daily by
diﬀerent psychogenic stressors (social defeat, water avoidance, light/
dark changes, forced swimming, soaked bedding, slanted cages, isola-
tion, crowding, shaking, restraint, foot shock, rat feces odor). Daily
schedule of the stressors is found in the Supplementary material. During
chronic variable stress, half of the animals received 300 mg/kg bw/day
rifaximin, a non-absorbable antibiotic (Sigma). Animals from diﬀerent
litters were randomly assigned to rifaximine/vehicle groups. Rifaximin
was dissolved in 5% hypromellose solution in drinking water. The other
half of mice (controls) received 5% hypromellose to drink. The ﬂuid
intake and body weight of the animals was monitored and rifaximin
concentration in the drinking water was adjusted.
Control animals were left undisturbed except once a week change of
bedding. Control mice were also randomly divided into rifaximin-
treated and vehicle-treated subgroups. With this grouping, four ex-
perimental groups were formed: 1: MS + CVS, rifaximin-treated; 2:
MS + CVS, vehicle treated; 3: No stress, rifaximin treated; 4: No stress,
vehicle treated.
Experimental design and timeline diagram are shown on Fig. 1.
2.3. Behavior tests
Sucrose consumption test was performed before CVS and one day
after chronic stress. Mice had free choice for 24 h between two bottles:
one with 1% sucrose solution and the other ﬁlled with tap water. The
position of the two bottles was switched after 12 h. Sucrose and tap
water intakes were assessed by weighing bottles. The sucrose con-
sumption was expressed as a percentage of total liquid intake. As we did
not habituate the animals to sucrose, this test measures neophobia ra-
ther than sucrose preference.
Anxiety-like behavior was studied in open ﬁeld and elevated plus
maze tests. In open ﬁeld test, mice were placed in the center of a
40x40x30cm, white, non-transparent plastic box and their exploration
was recorded from above for 10 min and then analyzed by the Noldus
EthoVision XT 10 program. The open ﬁeld was divided into 16 squares
by a 4x4 grid in the software. The four inner squares of the grid were
considered as central area. The apparatus was cleaned with tap water
and paper towel between subjects.
The ﬁrst ﬁve minutes of the mouse behavior in the open ﬁeld was
analyzed by Solomon Coder software. Four diﬀerent behavior elements
were diﬀerentiated in this analysis: walk, survey, rearing and grooming.
The analysis was carried out by two individuals blinded to subject
Fig. 1. Overview of the experimental design. MS: Maternal separation (3 h daily); CVS: Chronic variable stress (2x daily); OF: Open ﬁeld test; EPM: Elevated plus
maze test.
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treatment group. Walking was noted when the mouse changed its lo-
cation or turned as long as the front paws moved. Surveying was noted
when all paws were on the ﬂoor and head directed upwards. Rearing
was noted when two hind legs were on the ﬂoor and head directed
upwards.
The elevated plus maze (arm length-30 cm, arm width-7 cm, wall
height-30 cm platform height-80 cm) apparatus was made of dark-grey
painted plexiglass. Open arms were surrounded by 0,3 mm high ledges.
Mice were placed into the central area of the platform facing to one of
the open arms and were allowed to explore the apparatus for 5 min.
Mice were considered to enter a compartment when all four legs
crossed the lines separating the compartments. Videos were analyzed
by Noldus Observer software. Percentage of time spent in closed arms
was used to measure anxiety-like behavior. The platform was cleaned
with tap water and paper towel between subjects.
2.4. General procedure
At the end of the experiment, after decapitation (30 min after EPM)
trunk blood was collected on EDTA and plasma stored at −20 °C. This
blood sample was regarded as a measure of stress-induced CORT, as it
was collected at the time of maximal adrenocortical CORT release
provoked by EPM exposure as stressor. Adrenal glands, thymus, inter-
scapular brown adipose tissue (BAT), epididymal and subcutaneous
white adipose tissues (eWAT and sWAT) were collected, cleaned and
weighed for each mouse. Organ weights were normalized to ﬁnal body
weight and expressed as mg/g bw. Colon, mesenteric lymph nodes,
liver and colon content were harvested and stored at −70 °C until
assay.
2.5. Gut permeability test in vivo
To assess gut permeability, a new set of chronically stressed and
control animals (n = 22) were used. Half of these animals received
vehicle or rifaxinine (300 mg/kg) as above. After overnight of fasting,
all animals received FITC-labeled 4 kDa Dextran (Sigma-Aldrich) via
oral gavage (dose: 44 mg/kg; 100 mg/ml). 2 h later, 250–300 µl blood
was collected from the heart, centrifuged and serum was collected.
Serum samples were diluted with an equal volume of PBS and FITC
concentration was measured from 100 µl of diluted serum at excitation
485 nm and emission 535 nm wavelength using Cytation 5 Cell Imaging
Multimode reader (Biotek Instruments). Standard curve was obtained
by serial dilution of FITC-dextran solution in PBS (range: 0–16000 ng/
ml). Equal volume of non-hemolytic serum from non- gavaged mice was
added to the serial dilution before measurement. The intra- and inter-
assay coeﬃcient of variation was 5.1% and 6.7%, respectively.
2.6. Hormone, endotoxin, glucose and triglyceride measurement from
plasma
Plasma corticosterone was measured from 10 µl plasma by direct
RIA as described Zelena et al. (Zelena et al., 2003). The intra- and in-
terassay coeﬃcient of variation was 12.3% and 15.3%, respectively.
To determine plasma endotoxin levels, commercially available li-
mulus amebocyte lysate (LAL) assay was used in accordance of the
manufacturer’s instructions (Pierce LAL Chromogenic Endotoxin
Quantitation Kit, Thermo Scientiﬁc). The intra- and interassay var-
iances were: 5.3 and 5.6 CV% respectively.
Plasma glucose level was determined by Glucose Colorimetric
Detection Kit from plasma according to the manufacturer’s protocol
(Glucose Colorimetric Detection Kit, Invitrogen). For this assay, the
intra- and interassay variances were: 6.1 and 9.2 CV% respectively.
Plasma triglyceride (TG) level was measured by multiparameter
diagnostic device for triglycerides (MultiCare-in; Biochemical Systems
International Srl).
2.7. Gene expression analysis
Frozen colon tissue samples were homogenized by Bertin
Technology Minilys homogenizer in 300 µl TRI reagent. Then, total
mRNA was isolated from the homogenate using a Total mRNA Mini Kit
(Geneaid) according the manufacturer’s instruction. To eliminate
genomic DNA contamination, DNase I (Fermentas) treatment was used.
Sample quality control and the quantitative analysis were carried out
by NanoDrop (Thermo Scientiﬁc). cDNA synthesis was performed with
High Capacity cDNA Reverse Transcription Kit (Applied Biosystems).
Real-Time PCR was carried out in ABI StepOnePlus instrument (Applied
Biosystems) with Fast EvaGreen quantitative PCR master mix (Biotium)
and gene-speciﬁc primers. Primers (Microsynth) were designed in our
laboratory using Primer-BLAST software of the National Center for
Biotechnology Information (NCBI). Forward and reverse primers used
to quantify mRNA are listed in Supplementary table 2. Gene expression
was analyzed by the 2-ΔΔCT method using the ABI StepOne Software
v2.3 (Applied Biosystems). The amplicons were tested by melt curve
analysis on ABI StepOnePlus instrument (Applied Biosystems). Relative
changes in gene expression were normalized against GAPDH mRNA
expression. Reference gene was selected based on the NormFinder
software (Andersen et al., 2004).
2.8. Microbiome analysis
Total DNA was extracted from 200 mg colon content using QIAamp
DNA Stool Mini Kit (Qiagen) according to the manufacturer’s protocol.
Total genomic DNA concentration and quality control were checked by
using NanoDrop (Thermo Fisher). Targeting the bacterial 16S ribosomal
RNA gene, dominant taxons of the gut microbiome were analyzed by
real time quantitative PCR with Fast EvaGreen quantitative PCR master
mix (Biotium) and taxon speciﬁc primers (Supplementary table 3) on
ABI StepOnePlus instrument (Applied Biosystems). The position of the
speciﬁc primers in 16S rRNA gene and primer references are found in
Supplementary table 3. The primer speciﬁcity was tested by Melt Curve
Analysis. DNA samples were diluted to the same concentration 5 ng/µl.
Quantiﬁcation was done by using standard curves made from known
concentrations of the respective amplicon for each set of primers. Gene
expression was analyzed using ABI StepOne v2.3 program (Applied
Biosystems). The results are expressed in copy number (CN) and it was
calculated with the following formula: CN = A*6 × 1023/
(L*660)*1 × 109 ng/g; where A is the amount of the amplicon in ng, L
is the length of the amplicon.
2.9. Bacterial load in mesenteric lymph node
Mesenteric lymph nodes (MLN) were aseptically collected and
stored at−70 °C. Total DNA was isolated from MLN by Tissue Genomic
DNA Mini Kit (Geneaid) according to the manufacturer. DNA con-
centration and quality control were checked by using NanoDrop
(Thermo Scientiﬁc). Samples were diluted to the same DNA con-
centration. Then total DNA was ampliﬁed targeting bacterial 16S rRNA
gene by using an universal bacterial primer (Supplementary table 2).
Ampliﬁcation was processed by RT-PCR as described in 2.6.
2.10. Histology
After decapitation, a colon sample was removed, cleaned and placed
immediately into 10% buﬀered paraformaldehyde (pH = 7.4) for 24 h.
Fixed tissue was embedded in paraﬃn and sectioned 5 µm thick sec-
tions in two parallel series. One series was deparaﬃnized and stained
with haematoxylin & eosin (H&E). Images of stained colon sections
were captured under 20x magniﬁcation with Spot RT color digital
camera on Nikon Eclipse 6000 microscope. Mucosa thickness was
measured by using ImageJ software, in a blinded manner. From each
mouse, ﬁve sections were randomly selected, from each section, 10
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measurements were done and averaged.
F4/80 (murine macrophage marker) immunostaining was per-
formed on the second series of colon sections by standard im-
munohistochemical protocol. Slides were deparaﬃnized and rehy-
drated. Antigen retrieval pretreatment was performed with proteinase K
(Sigma; 10 mg/ml; diluted 1:25 in digestion puﬀer: 1 M Tris and 0,5M
EDTA). Then, endogenous peroxidase was blocked by 0,3% H2O2. Next,
slides were washed in KPBS (0,01 M potassium phosphate buﬀer,
0,154 M NaCl) and incubated in 2,5% normal rabbit serum for 1 h to
avoid nonspeciﬁc binding. Sections were incubated in anti-mouse F4/
80 antibody made in rat (BMA Biomedicals, T-2008; 1:50) overnight at
4 °C. After washing, sections were incubated in biotinylated secondary
antibody (Vector Laboratories, 1:250) for 1 h. Then, immunoreactivity
was visualized with Alexa FluorTM 488 Tyramide SuperBoostTM Kit,
according to the manufacturer’s instructions (Invitrogen by Thermo
Fisher Scientiﬁc). Slides were coverslipped with DAPI Fluoromount-G®
(SouthernBiotech) and scanned with Pannoramic® MIDI II Slide
Scanner. Images were analyzed with Caseviewer 2.3. software by two
diﬀerent investigators, who were blinded to treatment. For quantitative
analysis of the area% occupied by F4/80 immunoreactivity, ten images
from each mouse were randomly selected and re-opened in Image J
software. All images were set at a common threshold level and F4/80
positive areas were selected. Background subtraction procedure was
performed equally in each image. The entire immunoreactive area
fraction was then automatically measured by the program, with the
same threshold. Area % was measured separately for submucosa and
lamina propria.
2.11. Statistical analysis
Data are shown as means ± SEM. Statistical analysis was per-
formed by two-way ANOVA (GraphPad Prism 7) followed by Sidak’s
multiple comparison test. Sugar preference data was analyzed by re-
peated-measures ANOVA followed by Sidak’s post hoc test, time being
the repeated measure. In case of preCVS body weight data, unpaired t-
test was used. In all cases, diﬀerences were considered statistically




To examine the eﬀects of chronic stress and rifaximin on mouse
behavior, we observed and quantiﬁed four distinct elements: walking,
surveying, rearing and grooming during 5 min in novel environment
(Fig. 2A). Compared to no-stress controls, all mice which have been
exposed previously to MS + CVS displayed exaggerated locomotor-
related behavior. The frequencies of all four selected behavioral ele-
ments were increased signiﬁcantly in stressed mice [survey: F(1,
41) = 66.76; p < 0.0001; walk: F(1, 41) = 58.67; p < 0.0001; rear:
F(1, 41) = 49.28; p < 0.0001; groom: F(1, 41) = 33.35; p < 0.0001]
(Fig. 2B). Similarly, total duration of walking, rearing and grooming
were increased signiﬁcantly in stressed mice, however surveying de-
creased [surveying: F(1, 41) = 104.1; p < 0.0001; walking: F(1,
41) = 39.18; p < 0.0001; rearing: F(1, 41) = 37.69; p < 0.0001;
grooming: F(1, 41) = 17.38; p < 0.0002] (Fig. 2C). Rifaximin treat-
ment had no eﬀect on the behavioral pattern of control and MS + CVS
mice.
3.1.2. Open ﬁeld, EPM, sucrose consumption
Increased locomotion was detected during the open ﬁeld test in
MS + CVS mice. Velocity [F(1, 41) = 24.24; p < 0.0001] and dis-
tance moved [F(1, 41) = 24.29; p < 0.0001] was higher in chronically
stressed mice (Fig. 3A–B). In addition, stressed mice spent less time in
the center [F(1, 41) = 10.38; p = 0.0025] and their ﬁrst latency to
border was shorter than those of controls [F(1, 41) = 12.65;
p < 0.0010] (Fig. 3C–D).
To reveal anxiety-like behavior after MS + CVS, elevated plus maze
test was performed. As shown in Fig. 3.F preference for the open arms
of stressed mice was signiﬁcantly lower compared to control animals [F
(1, 28) = 13.95; p = 0.0009]. Average entries into the open arms, ﬁrst
latency to open and closed arm were also analyzed, however, we did
not detect signiﬁcant diﬀerences in these parameters (Supplementary
Fig. 1).
Neophobia was assessed by sucrose consumption tests before and
after the chronic stress procedure (Fig. 3G). MS + CVS resulted in a
signiﬁcant decrease of sucrose consumption (novelty) in stressed mice
[t = 4.148; DF = 19; p = 0.0022] and the same reduced sucrose
consumption was seen in CVS + antibiotic treated mice [t = 3.251;
DF = 19; p = 0.0167], however, there was no diﬀerence in control
groups. In each behavior tests (novel environment, open ﬁeld, elevated
plus maze and sucrose consumption based neophobia) rifaximin treat-
ment had no eﬀect.
3.2. Changes in body and organ weights
T-test revealed signiﬁcant pre-CVS body weight diﬀerence between
mice with postnatal maternal separation and controls [t = 2.69,
df = 20, p = 0.014] (Fig. 4A). During chronic variable stress, weight
gain between experimental groups was not signiﬁcantly diﬀerent [F
(1,18) = 0.2027; p = 0.8884)] (Fig. 4B).
Normalized adrenal weight was higher in all MS + CVS exposed
mice than in controls [F(1, 19) = 4.512; p = 0.047] (Fig. 4C). Two way
ANOVA did not reveal drug (rifaximin) eﬀect. Thymus weights were
not diﬀerent among the groups [F(1, 19) = 1.759; p = 0.2005].
Stress exposure resulted in signiﬁcant increases of adipose tissue
depots: normalized weights of subcutaneous- sWAT [F(1, 19) = 12.2;
p = 0.0024], epididymal- eWAT, white adipose tissues [F(1,
19) = 9.08; p = 0.0071] and interscapular brown adipose tissue, BAT
[F(1, 19) = 37.71; p < 0.0001] were higher in MS + CVS mice than
in controls.
3.3. Hormones and metabolic markers
During CVS procedure, basal (morning), pre-stress corticosterone
levels were signiﬁcantly higher in CVS exposed mice than in controls [F
(1, 18) = 7.181; p = 0.0153]. Two way ANOVA indicated no drug
eﬀect [F(1, 18) = 0.1965; p = 0.6629] (Fig. 5A).
Analysis of plasma corticosterone concentrations after acute EPM
exposure revealed no signiﬁcant diﬀerences among the treatment
groups [F(1, 19) = 0.226; p = 0.6399] (Fig. 5B).
Plasma glucose levels following acute stress were elevated in
chronically stressed mice compared to controls [F(1, 13) = 22.44;
p = 0.0004] (Fig. 5C).
In addition, post hoc test revealed elevated plasma TG level in
stressed mice [t = 2.627; DF = 18; p = 0.0339 compared to vehicle
control], while there was no diﬀerence between the two, antibiotic
treated groups (Fig. 5D).
3.4. Colon microbiome analysis
Antibiotic treatment reduced total DNA concentration in the colon
content (Fig. 6A). Interestingly, colonic DNA concentration in
MS + CVS + vehicle treatment group was more reduced than that of
the antibiotic treated mice and it was signiﬁcantly decreased compared
to the control group [t = 2.558; DF = 17; p = 0.0403], suggesting that
the abundance of microbiome in the colon is substantially reduced by
stress treatment.
Colon microbiome diversity was analyzed at the phylum level and
the results showed an increased abundance in the phylum of
Bacteriodetes [F(1,17) = 5.844; p = 0.0272] and Proteobacteria in
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response to stress, nevertheless rifaximin treatment signiﬁcantly atte-
nuated stress- induced Proteobacteria abundance [t = 2.665; DF = 17;
p = 0.0324 compared to control, t = 2.581; DF = 17; p = 0.0385
compared to antibiotic treatment] (Fig. 6B). Changes in Firmicutes,
Actinobacteria, Verrucomicrobia and Cyanobacteria were not signiﬁcant
(Fig. 6B-C). Amount of Clostridium sp. was determined at genus level.
Chronic stress resulted in increased abundance, however antibiotic
treatment normalized this stress-induced elevation [t = 2.707;
DF = 17; p = 0.0297 compared to control, t = 3.233; DF = 17;
p = 0.0098 compared to vehicle] (Fig. 6D).
3.5. Colon mucosa, tight junction protein expression and gut permeability
MS + CVS signiﬁcantly reduced the thickness of mucosa compared
to control [t = 3,082; DF = 19; p = 0.0122]. Mucosa thickness was not
diﬀerent in rifaximin-treated groups (Fig. 7A, B). Colonic mRNA ex-
pression (Fig. 7C) of tight junction proteins, occludin [F(1,
19) = 11.27; p = 0.0033] and tight junction proteins TJP1 [F(1,
19) = 6.26; p = 0.0216] and TJP2 [F(1, 19) = 6.613; p = 0.0187] but
not TJP3 was increased in both rifaximin treated groups, but remained
unchanged in response to stress. In case of MUC2 mRNA there was no
signiﬁcant diﬀerence between the groups [F(1, 19) = 4.012;
p = 0.597]. Expression of Reg3b, a C-type lectin with antimicrobial
activity, was signiﬁcantly elevated in chronically stressed mice.
Rifaximin treatment restored Reg3b mRNA level to that of the controls
[t = 3.811; DF = 19; p = 0.0024 compared to control, t = 4.398;
DF = 19; p = 0.0006 compared to vehicle, interaction: F(1,
19) = 10.21; p = 0.0048].
Next, we used FITC-labeled 4 kDa dextran assay to test gut perme-
ability in vivo and found increased gut permeability in chronically
stressed mice, while rifaximin treatment of these animals restored the
normal, non-stressed values [t = 2.72; DF = 18; p = 0.0301 compared
to control, t = 3.449; DF = 18; p = 0.0066 compared to vehicle, in-
teraction: F(1, 18) = 6.109; p = 0.0251] (Fig. 7D).
3.6. Gut permeability, macrophage inﬁltration, local- and systemic bacterial
load
Next, we checked whether increased gut permeability results in
local piling of macrophages. In control, vehicle-treated mice im-
munoreactivity corresponding to macrophage marker F4/80 was pri-
marily conﬁned to the submucosa. Essentially the same distribution was
revealed in non-stressed, rifaximin-treated mice (Fig. 8A). However, in
MS-CVS mice, an increase of F4/80 positive proﬁles and macrophage
inﬁltration to the lamina propria was detected. Rifaximin treatment of
MS-CVS animals restored the distribution of F4/80 positive macro-
phages to that seen in control animals (Fig. 8A). Quantitative histolo-
gical analysis of F4/80 + areas revealed signiﬁcant rifaximin eﬀect in
Fig. 2. Behavioral activity of control and chronically stressed mice with or without rifaximin treatment in a novel environment (open ﬁeld arena). Each row
represents one mouse (A). Frequency (B) and duration (C) of selected behavioral elements. Data were analyzed by two-way ANOVA (n = 9–14 per group).
Mean ± SEM values, **p < 0.01, ***p < 0.001, ****p < 0.0001 vs. control group.
D. Kuti, et al. Brain, Behavior, and Immunity xxx (xxxx) xxx–xxx
5
the submucosa [F(1, 19) = 6.316; p = 0.0211]. In the lamina propria
of MS-CVS animals, the area covered by F4/80 + proﬁles was sig-
niﬁcantly increased in stressed mice, which was reduced to that of the
controls in response to rifaximin treatment [t = 14.69; DF = 19;
p < 0.0001 compared to control, t = 14.78; DF = 19; p < 0.0001
compared to vehicle, interaction: F(1, 19) = 105.4; p < 0.0001],
(Fig. 8B).
Gut lymphatics are drained in mesenteric lymph nodes, which gate
intestinal bacteria and pathogen-associated molecular patterns, PAMPs.
To assess bacterial translocation in chronically stressed mice, we PCR-
ampliﬁed bacterial DNA from mesenteric lymph nodes using common
16S ribosomal primers. Compared to non-stressed controls, chronic
stress resulted in 50% elevation of bacterial load in the MLN
[t = 2.781; DF = 18; p = 0.0245]. Rifaximin administration interfered
with stress-induced increase of bacterial load (Fig. 8C).
To reveal if chronic stress induces systemic endotoxemia, plasma
LPS levels were measured. Higher LPS level was detected in plasma of
stressed mice than in the controls [t = 2.61; DF = 18; p = 0.0351] but
the increase of plasma LPS was not detected in antibiotic treated mice
(Fig. 8D).
4. Discussion
In the present study we demonstrate that “two hits” chronic stress
aﬀects colon microbiome, impairs gut barrier functions, resulting in
leaky gut as demonstrated by macrophage invasion to colon mucosa
and increased local- and systemic bacterial load. These changes are
accompanied by signs of increased anxiety-like behavior and neophobia
in stressed mice. Rifaximin, a non-absorbable, gut speciﬁc antibiotic,
given to chronically stressed mice, alleviated stress-induced increase of
Clostridia, improved gut permeability, mucosal erosion and inﬂamma-
tion, however had no impact on the stress-induced behavior.
Somatic (adrenal enlargement)-, hormonal (elevated plasma CORT)-
and metabolic (increased WAT depots, hyperglycemia and hyperlipi-
demia) parameters validated the present MS-CVS model as chronic
stress in mice (Zelena et al., 2005). Interestingly, stress-induced thymus
involution was not detected, in spite of elevated basal CORT levels.
There is a well-documented mutual interaction between the gut
microbiome and host stress response (Cryan and Dinan, 2012; Foster
et al., 2017). Chronic stress is an important environmental factor,
which triggers gut dysbiosis and in turn, altered microbiome has an
impact on neuroendocrine- autonomic and behavioral aspects of the
stress response. Growing evidence indicates a link between stress and
microbial dysbiosis (Cryan and Dinan, 2012; De Palma et al., 2014;
Watanabe et al., 2016). Previous studies from diﬀerent laboratories
revealed distinct stress-induced changes of the gut microbiome com-
position depending on the stressor (water avoidance (Xu et al., 2014;
Yoshikawa et al., 2017), repeated restraint (Maltz et al., 2018), social
Fig. 3. Anxiety-like behavior and neophobia after MS + CVS. Open ﬁeld results: Velocity during open ﬁeld test (A), distance moved (B) center preference (C) ﬁrst
latency in border (D) and exploration maps of the experimental mice (E). Open arm preference in elevated plus maze test (F). Data were analyzed by two-way ANOVA
(n = 9–14 per group). Mean ± SEM values, **p < 0.01, ****p < 0.0001 vs. control group. Sugar consumption of experimental mice before and after CVS
procedure (G). Data were analyzed by repeated measures two-way ANOVA followed by Sidak’s multiple comparison test (n = 5–7 per group). Mean ± SEM values,
*p < 0.05, **p < 0.01 vs. control group.
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defeat/disruption (Bailey et al., 2011; Langgartner et al., 2018;
Werbner et al., 2019) and origin of bacterial sampling (fecal (Gautam
et al., 2018), luminal (Szyszkowicz et al., 2017) mucosal (Galley et al.,
2014). General conclusion of these studies is that chronic psychological
stress results in outgrowth of Bacteroidetes and decreases the abundance
of Firmicutes. Here we conﬁrm and extend these observations to show
that MS-CVS “two hits” paradigm is also capable to increase Bacter-
oidetes and Proteobacteria in chronically stressed mice, which is ac-
companied here with an overall decrease of total bacterial DNA con-
centration in the colon content.
A number of studies have identiﬁed early life adversity as an im-
portant factor aﬀecting gut microbiome (Rincel et al., 2019). Studies in
rats, mice and Rhesus monkeys revealed decrease of microbial diversity
following maternal separation (Bailey and Coe, 1999) or limited nesting
(Moussaoui et al., 2016). Here, we have used the “two hits” model of
chronic adversity by combination of early life stress, maternal separa-
tion and chronic variable stress paradigm, both of which might have an
impact on gut microbiome. Future work should reveal lasting changes
and sensitization of postnatally stressed microbiome to challenges in
adulthood.
Among the bacterial species studied here, the copy number of
Clostridia increased signiﬁcantly as a result of MS-CVS stress paradigm.
This ﬁnding is in agreement with those of (Bailey et al., 2011; Pearson-
Leary et al., 2019; Watanabe et al., 2016). Although some Clostridia are
pathogenic and are responsible for diarrhea in the elderly, we did not
observe serious diarrhea or watery feces in our stressed mice.
Rifaximin, which is a non-absorbable antibiotic, speciﬁcally targets
Clostridia and other Gram negative and positive bacteria. Therefore, we
hypothesized that rifaximin treatment of mice exposed to MS-CVS will
restore microbiome related gut-brain axis and behavioral changes to
normal. Indeed, stress-induced Clostridia were signiﬁcantly attenuated
by antibiotic treatment. In addition, rifaximin administration prevented
stress-induced increases of Proteobacteria, but not Bacteroidetes. These
data conﬁrm previous ﬁndings that rifaximin do not signiﬁcantly aﬀect
the overall composition of the human fecal microbiome (Soldi et al.,
2015) and only mild changes are observed in mice (Jin et al., 2018).
More recently, rifaximin was recommended for treatment of post-in-
fectious irritable bowel disease (IBS) and related abdominal discomfort
Fig. 4. Eﬀect of chronic stress and rifaximin treatment on body weight gain and organ weights. Body weight diﬀerence before CVS (at PND50) (A) and body weight
gain during CVS (B). Normalized organ weights (C). Mean ± SEM. Data were analyzed by two-way ANOVA (n = 5–7 per group). In case of preCVS body weight
unpaired t-test was used. *p < 0.05, **p < 0.01, ****p < 0.0001 vs. control groups.
Fig. 5. Eﬀect of chronic stress on diﬀerent plasma markers. Basal corticosterone level during CVS (A). Eﬀect of single acute stress (EPM exposure) on corticosterone
level after chronic stress (B), plasma glucose level (C), plasma triglyceride level (D). Data were analyzed by two-way ANOVA, followed by Sidak’s multiple com-
parison test (n = 5–7 per group). Mean ± SEM values, *p < 0.05 vs. control group.
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(Acosta et al., 2016) (Ponziani et al., 2016). In search for the me-
chanism of rifaximin action, increased expression of gut tight junction
proteins emerged (Jin et al., 2018). We have conﬁrmed increased
mRNA levels of tight junction proteins occludin, tjp1 and tjp2, but not
tjp3, in colon samples of stressed and non-stressed, rifaximin treated
mice. Increased expression of tight junction proteins along with slightly
increased muc2 indicates improved gut barrier function after rifaximin
administration.
“Leaky gut” is generally held as a hallmark of chronic stress-related
pathologies (Camilleri, 2019; Maes et al., 2007). In the present MS-CVS
model, we did not detect stress-induced changes in colonic expression
of tight junction proteins (Occludin, TJP1-3) and muc2. However, we
did ﬁnd signiﬁcant decrease of mucosa thickness and signs of epithelial
damage. Furthermore, increased transcellular transport was detected in
the gut of chronically stressed mice by FITC-dextran method, indicating
impaired barrier function (Fukui, 2016). The leaky barrier should allow
various feed/microbiome related antigens to initiate local immune re-
sponses. Such an innate immune activation has been revealed by in-
ﬁltration of F4/80 positive macrophages into the lamina propria of MS-
CVS exposed mice, which was prevented by rifaximin treatment during
chronic variable stress. Gut lymphatics are drained in mesenteric lymph
nodes (MLN), where a signiﬁcant bacterial load has been revealed in
our chronically stressed mice. This ﬁnding is compatible with the report
by (Velin et al., 2004) where 30 times increased E coli passage was
Fig. 6. Diﬀerences in the microbiome composition after chronic stress and rifaximin treatment. Total DNA concentration of colon content (A), copy numbers of
bacterial phyla in the colon content (B,C). Copy number of Clostridium sp. in diﬀerent experimental groups (D). Data were analyzed by two-way ANOVA, followed by
Sidak’s multiple comparison test (n = 5–7 per group). Mean ± SEM values, *p < 0.05 vs. control group, #p < 0.05, ##p < 0.01, vs. MS + CVS-vehicle.
Fig. 7. Eﬀects of stress and rifaximin on colon mucosa. Representative images of hematoxylin-eosin stained colon sections (A) (scale bar: 20 µm) and bar graphs
showing mean values ± SEM of mucosa thickness (B), mRNA levels of diﬀerent permeability markers and antimicrobial defense-related genes from colon tissue (C),
changes in gut permeability as measured by serum concentration of orally administered FITC-dextran (mean values ± SEM) (D). Data were analyzed by two-way
ANOVA, followed by Sidak’s multiple comparison test (n = 5–7 per group). Mean ± SEM values, *p < 0.05, **p < 0.01, vs. non-stressed control group,
#p < 0.05, ##p < 0.01, ###p < 0.001, vs. corresponding vehicle-treated group.
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detected in chronically stressed rats, ex vivo. In addition to this local
bacterial translocation to MLN, signiﬁcant elevation of LPS was de-
tected in the plasma of MS-CVS mice, indicating systemic endotoxemia.
Rifaximin administration during CVS prevented the increase of LPS
plasma levels, suggesting that rifaximin eﬀects go beyond anti-patho-
genic activity. The endotoxemia reducing eﬀects of rifaximin has al-
ready been shown in chronic liver disease (Bajaj et al., 2013), however
the mechanisms of action and molecular targets remain unknown.
Another noteworthy ﬁnding of this study is the stress-induced co-
lonic upregulation of Reg3b. Reg3b is a C-type lectin, which belongs to
antimicrobial peptide (AMP) family and involved in gut barrier func-
tions (Shin and Seeley, 2019). Further studies are required to clarify if
increased expression of Reg3b mRNA may represent an adaptive com-
pensatory host mechanism to impaired barrier and increased bacterial
burden.
Chronic stress exposure is a risk factor for psychiatric disorders,
such as anxiety and depression, subsets of which are accompanied or
driven by activated immune system (Slattery et al., 2012; Renault and
Aubert, 2006). Parallel to stress-induced microbiome changes, chronic
stress increases gut permeability and results in a leaky gut, through
which bacterial cell wall components might reach the systemic circu-
lation, trigger toll like receptors and result in low grade systemic in-
ﬂammation. LPS and related proinﬂammatory cytokines activate the
HPA axis (Turnbull et al., 1998) and promote deterioration of stress-
induced anxiety (Anisman et al., 2002).
In search for the causal role of microbiome in the development of
stress-related psychopathologies, Langgartner et al. showed that stress-
induced psychobiological changes can be transmitted by fecal trans-
plantation from stressed to non-stressed mice (Langgartner et al., 2018).
In contrary, our present results suggest that settlement of stress-induced
changes in the gut does not alleviate MS-CVS-induced locomotor hy-
peractivity, anxiety-like symptoms in open ﬁeld and elevated plus maze
tests and anhedonia. One explanation for the resistance of stress-in-
duced behavior to improvement of gut and immune functions would be
the timing of rifaximin treatment. It is likely that behavior needs more
time than gut to recover from CVS. Another possibility would be that
early life adversity i.e. maternal separation results in permanent
changes in the gut ﬂora (Rincel et al., 2019) and behavior, which does
not change after antibiotic treatment in adulthood. Indeed, it has been
shown that early life events result in epigenetic modulation of stress/
anxiety-related genes such as hypomethylation of the Crh promoter in
the PVN of maternally deprived adult rats (Chen et al., 2012) and re-
duction in histone H3 acetylation at human/rat glucocorticoid receptor
(GR, NR3C1) promoter in the hippocampus (Suderman et al., 2012).
Finally, rifaximin reduced pathogenic bacteria and improved gut
barrier, however, did not enforce the abundance of beneﬁcial “psy-
chobiotic” bacteria. It has been shown that administration of certain
Lactobacilli and Biﬁdobacteria have anxiolytic/antidepressive eﬀects
(Borre et al., 2014; Bravo et al., 2011; Dinan et al., 2013).
Recent studies implicate that antibiotic usage in human and farm
animals results in dysbiosis, provoke systemic inﬂammation, which
might be responsible for long-term metabolic- (obesity), behavioral-
and mental changes. However, we did not detect any signiﬁcant be-
havioral changes in unstressed mice treated with antibiotic for 3 weeks.
Future work should focus on the interaction between systemic anti-
biotics and stress in regulation of microbiota-gut-brain axis.
In conclusion, combination of early life adversity with adult chronic
variable stress (CVS) paradigm in mice results in gut dysbiosis and
impaired gut barrier function along with increased locomotor activity,
anxiety-like behavior and neophobia. Rifaximin treatment during CVS
decreases stress-induced pathogenic bacteria, restores gut barrier
functions, reduces local and systemic bacterial load, however, does not
improve stress-induced behavioral changes.
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Fig.8. Macrophage inﬁltration to lamina propria, local- and systemic bacterial load. Representative images of F4/80 immunostained colon sections showing distinct
macrophage distribution (green-F4/80) in stressed and rifaximin-treated animals (on blue-DAPI background). (Scale bar: 100 µm) (A). Quantitative analysis of F4/80
immunostaining in the submucosa and lamina propria (B). Bacterial load in the mesenteric lymph node expressed as % of control-vehicle group (C). Plasma LPS
concentration in control, MS + CVS groups, with or without rifaximin treatment (D). Data were analyzed by two-way ANOVA, followed by Sidak’s multiple
comparison test (n = 5–7 per group). Mean ± SEM values, *p < 0.05, **p < 0.01, vs. control group, #p < 0.05, ##p < 0.01, ###p < 0.001, vs.
corresponding vehicle group. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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